The Journal of Aerosol Medicine and Pulmonary Drug Delivery is the only peer-reviewed journal delivering innovative, authoritative coverage of the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. The Journal is a forum for leading experts, addressing novel topics such as aerosolized chemotherapy, aerosolized vaccines, methods to determine toxicities, and delivery of aerosolized drugs in the intubated patient.
Pulmonary drug delivery
Airway reactivity and asthma treatment
Inhalation of particles and gases in the respiratory tract
Toxic effects of inhaled agents
Aerosols as tools for studying basic physiologic phenomena
The Journal of Aerosol Medicine and Pulmonary Drug Delivery impact factor increased, when compared to preceding years. The impact factor, also denoted as Journal impact factor (JIF), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal.
Latest Impact Factor (2020) is 2.846
Editor-in-Chief: Gerald C. Smaldone, MD, PhD, Pulmonary, Critical Care and Sleep Division, School of Medicine, State University of New York at Stony Brook
Associate Editor: Tim Corcoran, PhD, Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh
MEDLINE; PubMed; PubMed Central; Current Contents®/Clinical Medicine; Science Citation Index Expanded; Journal Citation Reports/Science Edition; Prous Science Integrity®; EMBASE/Excerpta Medica; Scopus; ProQuest databases
Business communications and advertising inquiries should be addressed to the publisher Mary Ann Liebert, Inc.